Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC16A3 | O15427 | 8/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.52 |
| ▸ | PPARG | P37231 | 5/20 | 0.50 |
| ▸ | MCTS1 | Q9ULC4 | 5/20 | 0.50 |
| ▸ | SLC16A1 | P53985 | 5/20 | 0.50 |
| ▸ | PPARA | Q07869 | 3/20 | 0.47 |
| ▸ | PPARD | Q03181 | 1/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.46 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2221138 | 0.89 | SLC16A3 (0.53) | SLC16A3PPARGMCTS1SLC16A1 | |
| SCHEMBL12223141 | 0.86 | ALDH1A1 (0.55) | SLC16A3ALDH1A1PPARGMAPK1L3MBTL1 | |
| SCHEMBL6679251 | 0.85 | ALDH1A1 (0.53) | SLC16A3ALDH1A1PPARGMCTS1SLC16A1 | |
| SCHEMBL11475913 | 0.84 | ALDH1A1 (0.52) | ALDH1A1PPARGPPARAMAPK1L3MBTL1 | |
| SCHEMBL11344345 | 0.83 | MAOB (0.47) | ALDH1A1PPARGMAPK1L3MBTL1SLC6A2 | |
| SCHEMBL874424 | 0.83 | ALDH1A1 (0.56) | ALDH1A1MAPK1L3MBTL1SLC6A2SLC6A3 | |
| SCHEMBL10384205 | 0.83 | SLC6A2 (0.50) | SLC16A3ALDH1A1PPARGMAPK1L3MBTL1 | |
| SCHEMBL2215266 | 0.83 | RXRA (0.46) | SLC16A3ALDH1A1PPARGMCTS1SLC16A1 | |
| SCHEMBL2352150 | 0.83 | RXRA (0.46) | SLC16A3PPARGMCTS1SLC16A1PPARA | |
| SCHEMBL8935661 | 0.83 | SLC16A3 (0.46) | SLC16A3PPARGMCTS1SLC16A1PPARA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 55 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2026107328-A1 | AGONISTS OF PARATHYROID HORMONE 1 AND INCRETIN RECEPTORS | SEPTERNA, INC. (US) | 2026-05-21 | — | — | WO | disclosed |
| US-11472810-B2 | Imidazopyrazinones as PDE1 inhibitors | H. LUNDBECK A/S (DK) | 2022-10-18 | — | — | US | disclosed |
| US-20210238182-A1 | IMIDAZOPYRAZINONES AS PDE1 INHIBITORS | H. LUNDBECK A/S (DK) | 2021-08-05 | — | — | US | disclosed |
| US-10912773-B2 | Combinations comprising substituted imidazo[1,5-a]pyrazinones as PDE1 inhibitors | H. LUNDBECK A/S (DK) | 2021-02-09 | — | — | US | disclosed |
| US-10905688-B2 | Combinations comprising substituted imidazo[1,5-α]pyrazinones as PDE1 inhibitors | H. LUNDBECK A/S (DK) | 2021-02-02 | — | — | US | disclosed |
| US-10858362-B2 | Imidazopyrazinones as PDE1 inhibitors | H. LUNDBECK A/S (DK) | 2020-12-08 | — | — | US | disclosed |
| EP-3532064-B1 | COMBINATION TREATMENTS COMPRISING IMIDAZOPYRAZINONES FOR THE TREATMENT OF PSYCHIATRIC AND/OR COGNITIVE DISORDERS | H LUNDBECK AS (DK) | 2020-07-29 | — | — | EP | disclosed |
| US-20190282572-A1 | COMBINATION TREATMENTS COMPRISING ADMINISTRATION OF IMIDAZOPYRAZINONES | H. LUNDBECKA/S (DK) | 2019-09-19 | — | — | US | disclosed |
| US-20190282571-A1 | COMBINATION TREATMENTS COMPRISING ADMINISTRATION OF IMIDAZOPYRAZINONES | H. LUNDBECK A/S (DK) | 2019-09-19 | — | — | US | disclosed |
| EP-3532053-A1 | COMBINATION TREATMENTS COMPRISING ADMINISTRATION OF IMIDAZOPYRAZINONES | H. Lundbeck A/S (DK) | 2019-09-04 | — | — | EP | disclosed |
| CN-1070487-C | Hexahydronaphthalene ester derivatives, their preparation and their therapeutic uses | SANKYO CO (JP) | 2001-09-05 | — | — | CN | disclosed |
| US-5491167-A | INHIBITORS OF CHOLESTEROL BIOSYNTHESIS | SANKYO COMPANY, LIMITED (JP) | 1996-02-13 | — | — | US | disclosed |
| CN-1098099-A | The hexahydro naphthalene ester derivative, their preparation and their treatment are used | SANKYO CO (JP) | 1995-02-01 | — | — | CN | disclosed |
| EP-0609058-A2 | Hexahydronaphthalene ester derivatives, their preparation and their therapeutic uses | SANKYO COMPANY LIMITED (JP) | 1994-08-03 | — | — | EP | disclosed |
| EP-0201221-B1 | 6-(1-ACYL-1-HYDROXY METHYL) PENICILLANIC ACID DERIVATIVES | PFIZER INC. (US) | 1990-08-01 | — | — | EP | disclosed |
| CN-1003712-B | Process for preparing 6- (1-acyl-1-hydroxymethyl or acetoxymethyl) penicillanic acid derivatives | 美国辉瑞有限公司 | 1989-03-29 | — | — | CN | disclosed |
| US-4762921-A | 6-(1-acyl-1-hydroxymethyl)penicillanic acid derivatives | PFIZER INC. (US) | 1988-08-09 | — | — | US | disclosed |
| US-4675186-A | 6-(1-acyl-1-hydroxymethyl)penicillanic acid derivatives | PFIZER INC. (US) | 1987-06-23 | — | — | US | disclosed |
| EP-0201221-A1 | 6-(1-acyl-1-hydroxy methyl) penicillanic acid derivatives | PFIZER INC. (US) | 1986-11-12 | — | — | EP | disclosed |
| CN-86102736-A | The preparation method and the application thereof of 6-(1-acyl group-1-methylol) penicillanic acid derivative | — | 1986-10-15 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190282571-A1 | COMBINATION TREATMENTS COMPRISING ADMINISTRATION OF IMIDAZOPYRAZINONES | PDE12, PDE1B, PDE1A | SLC16A3 4654/4885ALDH1A1 421/4885PPARG 565/4885 |
| US-10858362-B2 | Imidazopyrazinones as PDE1 inhibitors | PDE12, PDE4A, PDE5A | SLC16A3 3720/4885ALDH1A1 110/4885PPARG 973/4885 |
| US-20210238182-A1 | IMIDAZOPYRAZINONES AS PDE1 INHIBITORS | PDE12, PDE4A, PDE5A | SLC16A3 3720/4885ALDH1A1 110/4885PPARG 973/4885 |
| US-11472810-B2 | Imidazopyrazinones as PDE1 inhibitors | PDE12, PDE4A, PDE5A | SLC16A3 3720/4885ALDH1A1 110/4885PPARG 973/4885 |
| US-10912773-B2 | Combinations comprising substituted imidazo[1,5-a]pyrazinones as PDE1 inhibitors | PDE5A, PDE3A, PDE12 | SLC16A3 4387/4885ALDH1A1 151/4885PPARG 1213/4885 |
| US-10905688-B2 | Combinations comprising substituted imidazo[1,5-α]pyrazinones as PDE1 inhibitors | PDE1A, PDE12, PDE1B | SLC16A3 4785/4885ALDH1A1 92/4885PPARG 2143/4885 |
| US-20190282572-A1 | COMBINATION TREATMENTS COMPRISING ADMINISTRATION OF IMIDAZOPYRAZINONES | PDE12, PDE4A, PDE1A | SLC16A3 4026/4885ALDH1A1 602/4885PPARG 770/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.